Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that supplementation with CL22209, a standardized Asparagus racemosus root extract, significantly reduced menopausal symptoms and improved hormonal regulation among early perimenopausal women, with notable improvements in vasomotor and menstrual symptoms compared to placebo, while being safe and well-tolerated over 120 days.

This study found that 17β-estradiol inhibited RANTES production in human keratinocytes by suppressing nuclear factor κB activity, suggesting a potential mechanism for 17β-estradiol's modulation of psoriasis-related inflammation.

This article discusses immunohistochemical analysis of estrogen and progesterone receptors in endometrium and peritoneal endometriosis, introducing a new quantitative method, but reports no new experimental results.

This review explores how estrogens influence skin health and attractiveness in women, particularly with aging, but it reports no new clinical findings.

In this study, EFH-SLM cream demonstrated greater efficiency in reducing hair density compared to plain EFH cream in Swiss albino female mice, with significantly less skin irritation and inflammation observed, suggesting improved permeability and effectiveness of EFH when using the new cream formulation.

This study found that spironolactone reduced androgenic hormones in hirsute women but had only marginal effects on hair growth, making it no more advisable than other therapies.

This study found that a low dose of flutamide, both alone and combined with an oral contraceptive, effectively reduced hirsutism in women, with the combination showing more lasting effects post-treatment.

This review discusses the effectiveness and mechanisms of combined oral contraceptives in treating acne vulgaris but reports no new clinical results; the authors highlight their antiandrogenic effects for managing acne and related endocrine disorders.

This review examines hormonal therapies for acne in females, noting their effectiveness and encouraging further study and use to reduce antibiotic reliance, but it reports no new results.

This article compares cabergoline and bromocriptine for treating hyperprolactinemic amenorrhea and reports no specific findings.

This study found that oral spironolactone 100 mg daily for 24 weeks improved terminal hair counts and diameters in premenopausal women with female pattern hair loss when used alongside minoxidil, despite a higher incidence of menstrual irregularities.

The researchers reported that red clover extract supplementation in postmenopausal women improved subjective assessments of scalp hair, skin, libido, mood, sleep, and tiredness compared to placebo.

In this retrospective study, among transfeminine patients aged 19-81 receiving gender-affirming estrogen therapy, 100% achieved testosterone suppression without anti-androgens when serum estradiol exceeded 100pg/mL, predominantly using injectable estrogen.

This retrospective study found that cyproterone acetate, both alone and with estrogens, was safe, well tolerated, and induced modest feminizing effects in late-pubertal transgender female adolescents.

This report discusses the FDA's third denial of approval for Aveed, a long-acting testosterone injection by Endo Pharmaceuticals, citing continued safety concerns including severe side effects.

In this study, elevated prolactin and DHEA-S levels along with reduced SBP were observed in fertile non-obese women with moderate body hair compared to controls, and ethynylestradiol plus desogestrel or cyproterone acetate treatment improved clinical outcomes by increasing SBP.

This study found that treatment with cyproterone acetate and ethinyl oestradiol increased hair density in women with diffuse androgen-dependent alopecia, particularly when serum ferritin levels were above 40 μg/l.

This study reported that eflornithine cream, when used with laser hair removal, leads to faster reduction of unwanted facial hair in women and is similarly safe compared to the cream alone.

This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.

Hormonal contraception likely doesn't cause significant weight gain.

In this study, spironolactone and spironolactone plus metformin both significantly reduced hirsutism scores in women with PCOS, but the combination therapy was not more effective than spironolactone alone regarding BMI, hormone levels, or insulin resistance.

This review reports that 100 mg/day spironolactone improved hair growth more than placebo and was more effective in reducing hair growth than finasteride and low-dose cyproterone acetate, but its effectiveness for acne remains unclear due to small sample sizes.

This study found that polymers significantly improved the chemical and microbial stability of steroid hormones in liposome formulations over eight weeks, with finasteride showing the highest diffusion rate.

This study found that spironolactone reduced hirsutism scores in women without significant hormonal changes, suggesting its effectiveness primarily through peripheral mechanisms.

This meta-analysis found that in postmenopausal women with a history of breast cancer, 8 weeks of vaginal estrogen therapy while on aromatase inhibitors did not result in systemic absorption of sex hormones, suggesting potential safety for treating vulvovaginal atrophy in this context.

In this retrospective pharmacovigilance study, researchers analyzed over 7,900 adverse event reports related to aromatase inhibitors, identifying common side effects and toxicological mechanisms to highlight potential safety concerns in treating postmenopausal hormone receptor-positive breast cancer.

This review found some evidence suggesting that spironolactone can effectively reduce hirsutism in women but did not support its use for treating acne vulgaris.

This study found that cyproterone acetate, given with ethinyl oestradiol, significantly reduced hirsutism in women after 12 months, although improvements reversed once cyproterone acetate was stopped.